Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines

This study has been completed.
Information provided by:
Montefiore Medical Center Identifier:
First received: July 20, 2005
Last updated: February 15, 2008
Last verified: February 2008
Migraines are a specific type of headache that frequently recur and are very painful. Although there are many medications that are effective against migraines, none of these medications cure 100% of migraines. Another problem with migraines is that although many times they get better after intravenous (IV) treatment in the emergency room (ER), about 1/3 of the time migraines recur the next day. The purpose of this research project is to see if adding a medication called dexamethasone to standard ER therapy will help patients get better quicker and stay pain-free more often than if they receive placebo.

Condition Intervention Phase
Drug: dexamethasone 10mg IV
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Parenteral Corticosteroids as Adjuvant Therapy for Migraine Headaches

Resource links provided by NLM:

Further study details as provided by Montefiore Medical Center:

Primary Outcome Measures:
  • Persistent headache pain free at 24 hours [ Time Frame: 24 hours ]

Secondary Outcome Measures:
  • Pain and disability scores at 2 and 24 hours [ Time Frame: 24 hours ]

Enrollment: 205
Study Start Date: July 2005
Study Completion Date: August 2006
Primary Completion Date: August 2006 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: dexamethasone 10mg IV
  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Migraine with or without aura; probable migraine without aura

Exclusion Criteria:

  • Secondary headache
  • Allergy, contraindication or intolerance to study medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00122278

United States, New York
Jacobi Medical Center
Bronx, New York, United States, 10461
Columbia University Medical Center
Manhattan, New York, United States
St. Lukes Hospital
New York, New York, United States
Sponsors and Collaborators
Montefiore Medical Center
Principal Investigator: Benjamin W. Friedman, MD, MS Albert Einstein College of Medicine, Inc.
  More Information

Responsible Party: Benjamin Friedman, Albert Einstein College of Medicine Identifier: NCT00122278     History of Changes
Other Study ID Numbers: MMC: 05-02-032S or CCI: 05-030
Study First Received: July 20, 2005
Last Updated: February 15, 2008

Keywords provided by Montefiore Medical Center:
migraine, emergency department, dexamethasone
Migraine with or without aura or probable migraine without aura as defined by ICHD, 2nd edition

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Dexamethasone acetate
Dexamethasone 21-phosphate
BB 1101
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 24, 2017